Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Balduzzi, Adriana  [Clear All Filters]
2015
Faraci M, Matthes-Martin S, Lanino E, Morreale G, Ferretti M, Giardino S, Micalizzi C, Balduzzi A. Two pregnancies shortly after transplantation with reduced intensity conditioning in chronic myeloid leukemia. Pediatr Transplant. 2015.
2019
Kuhlen M, Kunstreich M, Niinimäki R, Dunstheimer D, Lawitschka A, Bardit E, Willasch A, Bader P, Högler W, Peters C, et al. Guidance to bone morbidity in children and adolescents undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
Balduzzi A, Dalle J-H, Wachowiak J, Yaniv I, Yeşilipek A, Sedlacek P, Bierings M, Ifversen M, Sufliarska S, Kalwak K, et al. TRANSPLANTATION IN CHILDREN AND ADOLESCENTS WITH ACUTE LYMPHOBLASTIC LEUKEMIA FROM A MATCHED DONOR VERSUS AN HLA-IDENTICAL SIBLING: IS THE OUTCOME COMPARABLE? RESULTS FROM THE INTERNATIONAL BFM ALL SCT 2007 STUDY. Biol Blood Marrow Transplant. 2019.
2020
Willasch AManfred, Peters C, Sedlacek P, Dalle J-H, Kitra-Roussou V, Yeşilipek A, Wachowiak J, Lankester A, Prete A, Hamidieh AAli, et al. Myeloablative conditioning for allo-HSCT in pediatric ALL: FTBI or chemotherapy?-A multicenter EBMT-PDWP study. Bone Marrow Transplant. 2020.
Magnani CF, Gaipa G, Lussana F, Belotti D, Gritti G, Napolitano S, Matera G, Cabiati B, Buracchi C, Borleri G, et al. Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities. J Clin Invest. 2020.
2021
Ottaviano G, Achini-Gutzwiller F, Kalwak K, Lanino E, Faraci M, Rao K, Chiesa R, Amrolia P, Bonanomi S, Rovelli A, et al. Impact of in vivo lymphodepletion on outcome in children with non-malignant disorders receiving peripheral blood stem cell transplantation. Transplant Cell Ther. 2021.
2022
Laetsch TW, Maude SL, Rives S, Hiramatsu H, Bittencourt H, Bader P, Baruchel A, Boyer M, de Moerloose B, Qayed M, et al. Three-Year Update of Tisagenlecleucel in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia in the ELIANA Trial. J Clin Oncol. 2022:JCO2200642.
2023
Cseh A, Galimard J-E, De La Fuente J, Isgrò A, Zecca M, Garwer B, Biffi A, Aljurf M, Sundin M, Belendez C, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. Br J Haematol. 2023.
Rossig C, Pearson AD, Vassal G, Scobie N, Bird N, Blanc P, H Vormoor J, Calkoen FG, Locatelli F, Del Bufalo F, et al. Chimeric Antigen Receptor (CAR) T-Cell Products for Pediatric Cancers: Why Alternative Development Paths Are Needed. J Clin Oncol. 2023:JCO2301314.
Nucera S, Sindoni MM, Bugarin C, Villa T, Biondi A, Balduzzi A, Gaipa G. A novel flow-cytometric based method to assess post-HSCT donor chimerism exploiting RNA hybridization. Bone Marrow Transplant. 2023.
2024
Oostenbrink LVE, von Asmuth EGJ, van der Zijde CMJol-, Jansen-Hoogendijk AM, Vervat C, Bredius RGM, van Tol MJD, Schilham MW, Sedlacek P, Ifversen M, et al. Anti-T-lymphocyte globulin exposure is associated with acute graft-versus-host disease and relapse in pediatric acute lymphoblastic leukemia patients undergoing hematopoietic stem cell transplantation: a multinational prospective study. Haematologica. 2024.
Saglio F, Pagliara D, Zecca M, Balduzzi A, Cattoni A, Prete A, Tambaro FPaolo, Faraci M, Calore E, Locatelli F, et al. Long-term complications after allogeneic hematopoietic stem cell transplantation for pediatric patients with acute leukemia or myelodysplastic syndrome given either a Treosulfan- or a Busulfan-based conditioning regimen: results of an AIEOP (Associazione . Transplant Cell Ther. 2024.